Bpifrance s’associe à Capgemini pour la création de sa Digital Factory de nouvelle génération
10 nov. 2023 02h30 HE
|
Capgemini SE
Relations presse Capgemini : Hélène Delannet Tel. : + 33 1 57 99 44 51 E-mail : helene.delannet@capgemini.comRelations presse Bpifrance : Juliette FontanillasTel. : +33 6 72 76 08 09 E-mail :...
Bpifrance partners with Capgemini for the creation of a next generation digital factory
10 nov. 2023 02h30 HE
|
Capgemini SE
Media Relations Capgemini: Hélène Delannet Tel.: +33 1 57 99 44 51 E-mail: helene.delannet@capgemini.comMedia Relations Bpifrance: Juliette FontanillasTel.: +33 6 72 76 08 09 E-mail:...
Diaccurate est soutenue par Bpifrance pour son Programme DIACC2020 portant sur le développement de nouveaux composés cytotoxiques conjugués à des anticorps thérapeutiques (ADCs)
05 janv. 2023 02h00 HE
|
DIACCURATE
La plateforme DIACC2020 ambitionne de mettre au point une nouvelle génération de composés cytotoxiques pouvant être conjugués à des anticorps thérapeutiquesElle s’appuie sur les propriétés uniques du...
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)
05 janv. 2023 02h00 HE
|
DIACCURATE
The DIACC2020 platform aims to develop a new generation of cytotoxic compounds to be conjugated to therapeutic antibodies The Program stems from the unique properties of its proprietary compound...
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
13 juin 2022 01h00 HE
|
ImCheck Therapeutics SAS
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
15 sept. 2020 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Announces Investment by BB Pureos Bioventuresto Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced...
Innate Pharma obtient un financement public de 6,8M€ pour ses activités de recherche et développement dans la COVID-19
11 août 2020 01h00 HE
|
INNATE PHARMA
Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce avoir obtenu un financement de 6,8 M€ dans le cadre de l’appel à projet PSCP-COVID...
Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities
11 août 2020 01h00 HE
|
INNATE PHARMA
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the Company has obtained funding of €6.8M under the PSPC-COVID call for projects...
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance
11 mars 2020 13h00 HE
|
Deinove
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new...
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
04 déc. 2019 00h45 HE
|
ImCheck Therapeutics SAS
-- Bpifrance and Pfizer Ventures co-led international investor syndicate -- Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class...